

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 38/16, 39/00, 39/395, C07K 5/00, 14/00		A1	(11) International Publication Number: WO 95/05191
			(43) International Publication Date: 23 February 1995 (23.02.95)
(21) International Application Number: PCT/US94/09193		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).	
(22) International Filing Date: 12 August 1994 (12.08.94)			
(30) Priority Data: 08/106,120 13 August 1993 (13.08.93) US 08/238,169 4 May 1994 (04.05.94) US			
(71) Applicant: UAB RESEARCH FOUNDATION [US/US]; Suite 1120G-AB, 701 South 20th Street, Birmingham, AL 35294-0111 (US).			
(72) Inventors: MURPHY-ULLRICH, Joanne, E.; 939 Landale Road, Birmingham, AL 35222 (US). ROBERTS, David, D.; 6808 Persimmon Tree Road, Bethesda, MD 20817 (US). KRUTZSCH, Henry, C.; 9704 De Paul Drive, Bethesda, MD 20817 (US). SCHULTZ-CHERRY, Stacey; 1501 Valley View Drive, Birmingham, AL 35209 (US).			
(74) Agents: NEEDLE, William, H. et al.; Needle & Rosenberg, Suite 1200, 127 Peachtree Street NE, Atlanta, GA 30303-1811 (US).		Published <i>With international search report.</i>	
(54) Title: METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF- β ACTIVITY			
(57) Abstract <p>The invention provides a method of stimulating TGF-β activity, comprising contacting latent TGF-β with an amount of TSP or an activating peptide from TSP effective to convert latent TGF-β to active TGF-β. Also provided is a method of inhibiting the stimulation of TGF-β activity, comprising contacting latent TGF-β with a ligand specific for TSP effective to bind TSP and prevent activation of TGF-β or an amount of an inhibiting peptide having a sequence that corresponds to a sequence of four consecutive amino acids of TSP, effective to inhibit the conversion of latent TGF-β to active TGF-β. The invention also provides a method of enhancing wound healing, comprising administering to a wound site an amount of TSP or an activating peptide from TSP effective to convert latent TGF-β to active TGF-β, the activation of TGF-β resulting in enhanced wound healing. A method of preventing fibrosis stimulated by TGF-β in pathology is also provided. The method comprises administering to a site of potential fibrosis an amount of a ligand specific for TSP effective to bind TSP and inhibit activation of TGF-β or an inhibiting peptide from TSP effective to inhibit conversion of latent TGF-β to active TGF-β, resulting in reduced fibrosis. The invention also provides a method of blocking TGF-β-mediated inhibition of endothelial cell proliferation comprising contacting endothelial cells with a ligand specific for TSP effective to bind TSP and inhibit activation of TGF-β or an inhibiting peptide from TSP effective to inhibit conversion of latent TGF-β to active TGF-β, resulting in proliferation of endothelial cells.</p>			

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 38/00, 38/16, 39/00, 39/395, C07K 5/00, 14/00		A1	(11) International Publication Number: WO 95/05191
			(43) International Publication Date: 23 February 1995 (23.02.95)
(21) International Application Number: PCT/US94/09193		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).	
(22) International Filing Date: 12 August 1994 (12.08.94)			
(30) Priority Data: 08/106,120 13 August 1993 (13.08.93) US 08/238,169 4 May 1994 (04.05.94) US			
(71) Applicant: UAB RESEARCH FOUNDATION [US/US]; Suite 1120G-AB, 701 South 20th Street, Birmingham, AL 35294-0111 (US).			
(72) Inventors: MURPHY-ULLRICH, Joanne, E.; 939 Landale Road, Birmingham, AL 35222 (US). ROBERTS, David, D.; 6808 Persimmon Tree Road, Bethesda, MD 20817 (US). KRUTZSCH, Henry, C.; 9704 De Paul Drive, Bethesda, MD 20817 (US). SCHULTZ-CHERRY, Stacey; 1501 Valley View Drive, Birmingham, AL 35209 (US).			
(74) Agents: NEEDLE, William, H. et al.; Needle & Rosenberg, Suite 1200, 127 Peachtree Street NE, Atlanta, GA 30303-1811 (US).		Published <i>With international search report.</i>	
(54) Title: METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF- β ACTIVITY			
(57) Abstract <p>The invention provides a method of stimulating TGF-β activity, comprising contacting latent TGF-β with an amount of TSP or an activating peptide from TSP effective to convert latent TGF-β to active TGF-β. Also provided is a method of inhibiting the stimulation of TGF-β activity, comprising contacting latent TGF-β with a ligand specific for TSP effective to bind TSP and prevent activation of TGF-β or an amount of an inhibiting peptide having a sequence that corresponds to a sequence of four consecutive amino acids of TSP, effective to inhibit the conversion of latent TGF-β to active TGF-β. The invention also provides a method of enhancing wound healing, comprising administering to a wound site an amount of TSP or an activating peptide from TSP effective to convert latent TGF-β to active TGF-β, the activation of TGF-β resulting in enhanced wound healing. A method of preventing fibrosis stimulated by TGF-β in pathology is also provided. The method comprises administering to a site of potential fibrosis an amount of a ligand specific for TSP effective to bind TSP and inhibit activation of TGF-β or an inhibiting peptide from TSP effective to inhibit conversion of latent TGF-β to active TGF-β, resulting in reduced fibrosis. The invention also provides a method of blocking TGF-β-mediated inhibition of endothelial cell proliferation comprising contacting endothelial cells with a ligand specific for TSP effective to bind TSP and inhibit activation of TGF-β or an inhibiting peptide from TSP effective to inhibit conversion of latent TGF-β to active TGF-β, resulting in proliferation of endothelial cells.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF- β ACTIVITY

5

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates to a method of regulating TGF- β activity. In particular, the present invention relates to a method of stimulating TGF- β activity
10 by the application of TSP or specific peptides from TSP which stimulate TGF- β activity or inhibiting TGF- β activity by the application of antibodies against TSP or specific peptides from TSP which inhibit TGF- β activity.

BACKGROUND ART

15 Transforming growth factor- β (TGF- β) is a member of a family of growth, differentiation, and morphogenesis autocrine and paracrine factors (3,26). TGF- β can affect diverse cellular functions in virtually all cell types. Depending on the cell type and its extracellular environment, these effects can be either positive or negative. TGF- β inhibits the proliferation of endothelial cells *in vitro* (31), but
20 stimulates angiogenesis *in vivo* (39). TGF- β has also been shown to enhance or inhibit the proliferation of fibroblasts depending on the nature of the substrate and the mitogens present (3). Myoblast differentiation can also be induced or blocked by TGF- β depending on the availability of mitogens (25, 45).

25

TGF- β 1 is a disulfide-linked homodimer that is synthesized as part of a latent precursor molecule (26). The latent precursor molecule is 390 amino acids in length and consists of an N-terminal 278 amino acid latency associated peptide (LAP) and a C-terminal 112 amino acid active domain (15-17). The proregion of TGF- β is unique in that it remains non-covalently attached to the active region after intracellular
30 proteolytic processing and secretion (15). Association of the LAP with the mature peptide region confers latency: the LAP-associated growth factor is unable to interact with its cellular receptors. The LAP contains three N-linked glycosylation sites, two of which have mannose-6-phosphate residues (8,28,38). These carbohydrate structures

may be important for latency since endoglycosidase F treatment leads to activation of TGF- β (28). The disulfide-bonded dimeric structure of LAP is critical for latency, since site-directed mutagenesis of critical cysteine residues (cys 223, 225) in the LAP abolishes the latency function (9). The active domain contains nine conserved cysteine
5 residues that participate in inter-and intrachain disulfide bonding (27).

TGF- β is secreted by most cell types as a latent complex (27,37). Since TGF- β synthesis and TGF- β receptor expression are not highly regulated, primary regulation of TGF- β activity occurs by controlling conversion of the latent
10 TGF- β complex to the active molecule. Physicochemical activation can occur by extremes of pH, heat, chaotropic agents, and deglycosylation (6,27,28,37). Activation *in vivo* is more complex and not well understood. There is evidence from cell culture models that activation may occur through binding of the latent molecule to mannose 6-phosphate receptors (12,21), by plasmin-mediated proteolytic processing
15 (4,23,40,41), and/or by processing in acidic cellular microenvironments (20). In some systems, activation of latent TGF- β by plasmin is relatively inefficient (41). In addition, there are reports of TGF- β activation occurring independently of these mechanisms (19). These results suggest that additional mechanisms of latent TGF- β activation may exist.

20

TGF- β has been demonstrated, through numerous studies, to play a significant role in wound healing and fibrosis. The three phases of inflammation, granulation tissue formation and biosynthesis of the extracellular matrix, are identical in both the wound healing process and the development of fibrosis. A fine balance in
25 the biosynthetic and degradative pathways involved in extracellular matrix biosynthesis appears to be determinative of whether proper wound healing or fibrosis results. Due to its function of regulating genes critically involved in extracellular matrix formation, TGF- β significantly influences this phase of tissue regeneration, the final outcome of which is either wound healing or fibrosis. (46). Thus, sensitive regulation of TGF- β
30 activity in this process will permit control of the wound healing and fibrotic processes.

The thrombospondins (TSP) are a growing family of multidomain glycoproteins (5,30,48,49). TSP1 is the best characterized and serves as the prototypical TSP molecule. TSP, a disulfide-linked trimer (450,000 daltons) present in connective tissues and in platelet alpha granules, is associated with TGF- β as an active complex in the releasate of stimulated platelets (5,14,30,34). TSP is secreted and incorporated into the extracellular matrix of a number of cells in culture (1-5). TSP, like TGF- β , has diverse effects on cellular functions that vary with cell type. TSP can inhibit endothelial proliferation and migration (2,34,42,51), but stimulates the growth of smooth muscle cells and dermal fibroblasts (36,52). TSP may also serve as both an attachment protein and an anti-adhesive molecule as shown by its ability to cause disassembly of focal adhesions in endothelial cells (33). TSP also plays a role in angiogenesis, fibrinolysis, platelet aggregation, and inflammation (1-5).

TSP is present transiently in wound environments and its synthesis is rapidly induced by growth factors, including TGF- β (50). TSP is detectable in incisional wound margins for 2-7 days, after which it localizes around vascular channels near the wound. Although the role of TSP is not yet clearly understood, it has been speculated that TSP may facilitate cell migration into the wound site or possibly act as a localized growth promoting agent (49).

20

There are three sequences in TSP known as type 1 repeats. Each repeat consists of approximately 60 amino acids, has six conserved cysteine residues and has approximately 47% sequence homology to similar repeats found in the human complement component, properdin. Within the type 1 repeats of TSP, there are two well defined consensus sequences, CSVTCG (SEQ ID NO:1) and WSXW (SEQ ID NO:2). CSVTCG (SEQ ID NO:1) inhibits metastasis of melanoma cells in a murine lung colonization assay (47), and promotes cell adhesion (53,54). Tolsma *et al.* showed that CSVTCG (SEQ ID NO:1) inhibits angiogenesis *in vivo* using a corneal neovascularization assay (55).

30

The sequence WSXW (SEQ ID NO:2) binds specifically to sulfated glycoconjugates and promotes cell adhesion and chemotaxis (56). The binding of TSP to the gelatin-binding domain of fibronectin can be blocked using the peptide GGWSHW (SEQ ID NO:3) (57). This sequence is also conserved within members of the TGF- β and cytokine receptor superfamilies (58,59).

The present invention provides a method for activation of latent TGF- β by TSP and a method for inhibiting the activation of latent TGF- β by binding TSP with a specific ligand. This invention also provides specific TSP peptides which activate latent TGF- β and TSP peptides which inhibit activation of latent TGF- β . These peptides from TSP can both positively and negatively modulate TGF- β levels at nanomolar to micromolar concentrations, and, therefore, can be used as therapeutic agents *in vivo* for the promotion of wound healing and inhibition of fibrosis.

15

SUMMARY OF THE INVENTION

The invention provides a method of stimulating TGF- β activity, comprising contacting latent TGF- β with an amount of TSP or an activating peptide from TSP effective to convert latent TGF- β to active TGF- β . Also provided is a method of inhibiting the stimulation of TGF- β activity, comprising contacting latent TGF- β with a ligand specific for TSP effective to bind TSP and prevent activation of TGF- β or an amount of an inhibiting peptide having a sequence that corresponds to a sequence of four consecutive amino acids of TSP, effective to inhibit the conversion of latent TGF- β to active TGF- β .

25

The invention also provides a method of enhancing wound healing, comprising administering to a wound site an amount of TSP or an activating peptide effective to convert latent TGF- β to active TGF- β , the activation of TGF- β resulting in enhanced wound healing.

30

A method of preventing fibrosis stimulated by TGF- β in pathology is also provided. The method comprises administering to a site of potential fibrosis an amount of a ligand specific for TSP effective to bind TSP and inhibit activation of TGF- β or an inhibiting peptide from TSP effective to inhibit conversion of latent TGF- β to active TGF- β , resulting in reduced fibrosis.

The invention also provides a method of blocking TGF- β -mediated inhibition of endothelial cell proliferation comprising contacting the endothelial cells with a ligand specific for TSP effective to bind TSP and inhibit activation of TGF- β or an inhibiting peptide from TSP effective to inhibit conversion of latent TGF- β to active TGF- β , resulting in proliferation of endothelial cells.

DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention may be understood more readily by reference to the following detailed description of specific embodiments and the Examples included herein.

In one embodiment, the present invention provides a method of stimulating TGF- β activity, comprising contacting latent TGF- β with an amount of purified TSP or a purified activating peptide from TSP effective to convert latent TGF- β to active TGF- β . "Activated TGF- β " or "TGF- β activity" as used herein describes the TGF- β protein present in a conformation whereby the TGF- β protein exerts an effect on cells to which it is exposed, the effect being proliferation, differentiation, angiogenesis, etc. "Latent TGF- β " as used herein means the TGF- β protein present in a conformation whereby the active domain of the TGF- β protein is complexed to LAP and therefore, does not exert an effect on cells to which it is exposed. The term "activating peptide" as used herein is defined as a peptide sequence or peptide mimetic, either synthetic or generated from a native protein or by recombinant methods, comprising a minimum of three amino acids, which when exposed to latent TGF- β , converts latent TGF- β to activated TGF- β . The peptides of the invention correspond

to sequences of TSP or they can be derived from the functional sequences of TSP. The term "purified" as used herein means separated from other proteins, peptides and contaminants.

5 In the method of stimulating TGF- β activity by contacting latent TGF- β with an amount of an activating peptide from TSP, the activating peptide can be from the first, second and third type 1 repeat regions of TSP. For example, SEQ ID NOS: 5, 9, 14, 15 and 16 are from the second type 1 repeat region. As used herein, "second type 1 repeat region" means the second type 1 repeating sequence unit, as
10 measured from the amino terminus of the three type 1 repeats and consisting of amino acids 412-473 of human TSP1. The activating peptide can be selected from the group consisting of: KRFK (SEQ ID NO:5), HRFK (SEQ ID NO:6), RKPK (SEQ ID NO:7), QRFK (SEQ ID NO:8), KRFKQDGG (SEQ ID NO:9), RWRPWTAWSE (SEQ ID NO:10), TAYRWRLSHRPKTGIRV (SEQ ID NO:11),
15 KRFKQDGGASHASP (SEQ ID NO:12), KRFKQDGGASHASP (SEQ ID NO:13), KRFKQDGGWSHWSP (SEQ ID NO:14), KRFKQDGGWSHWSPWSS (SEQ ID NO:15), KRFKQDGGWSHW (SEQ ID NO:16) and KRFKQDGGWWSP (SEQ ID NO:17) or can consist of the amino acid sequence RFK (SEQ ID NO:18). The activating peptide may contain partial or full retro-inverso modifications of the
20 sequences or appropriate non-natural amino acids. Such sequences as well as others corresponding to or derived from TSP are determined to be activating sequences by screening for TGF- β activating function in a soft agar NRK colony formation assay and an endothelial cell proliferation assay as described in the Examples.

25 Also provided is a method of inhibiting the stimulation of TGF- β activity by contacting cells producing TGF- β with an amount of a ligand specific for TSP effective to bind TSP and prevent activation of TGF- β . "Specific" as used herein describes an antibody or other ligand that does not cross react substantially with any moiety other than the one specified, in this case, TSP. As contemplated herein, the
30 ligand includes any reagent which binds TSP, for example, an intact antibody, a fragment of an antibody or another reagent that has specific reactivity with TSP.

Ligands, such as antibodies can be those provided in the Examples or can be made as described in the art using routine procedures (61).

In another embodiment, the invention provides a method of inhibiting the stimulation of TGF- β activity comprising contacting latent TGF- β with an amount of a purified inhibiting peptide from TSP effective to inhibit the conversion of latent TGF- β to activated TGF- β . As used herein, "inhibitory peptide" means a peptide sequence comprising a minimum of four amino acids derived from the functional regions of TSP which, when exposed to latent TGF- β , inhibits the conversion of latent TGF- β to active TGF- β . The purified inhibiting peptide can have a sequence that corresponds to a sequence of four consecutive amino acids of TSP, effective to inhibit the conversion of latent TGF- β to active transforming TGF- β .

In the method of inhibiting the stimulation of TGF- β activity, the inhibiting peptide can be from the first, second and third type 1 repeat region of TSP. For example, SEQ ID NOS: 25, 26, 27 and 3 are from the second type 1 repeat. The inhibiting peptide derived from TSP can consist of the amino acid sequence GGWSHW (SEQ ID NO:3) or selected from the group consisting of: WNDWI (SEQ ID NO:19), WSSWS (SEQ ID NO:20), LSKL (SEQ ID NO:21), AAWSHW (SEQ ID NO:22), DGWSPW (SEQ ID NO:23), GGWGPW (SEQ ID NO:24), WSPWS (SEQ ID NO:25), GWSHW (SEQ ID NO:26) and WSHWS (SEQ ID NO:27). The activating peptide may contain partial or full retro-inverso modifications of the sequences or appropriate non-natural amino acids. These and other sequences derived from TSP are determined to be inhibiting sequences by screening for inhibition of TGF- β activating function in a soft agar NRK colony formation assay as described in the Examples.

TGF- β is known to regulate wound healing. Thus, the present invention also provides a method of enhancing wound healing by administering to a wound site an amount of purified TSP or a purified activating peptide from TSP effective to convert latent TGF- β to active TGF- β , the activation of TGF- β resulting in

enhanced wound healing. The activating peptides can be those described herein. As used herein, "enhanced wound healing" is defined as a statistically significant increase in the rate of wound healing, as determined by histological analysis, tensile strength and total protein and collagen content of a wound treated with an amount of TSP or an activating peptide from TSP, as compared to a similar untreated wound or a similar wound treated with a non-activating control. Histological analysis includes examination for the presence of fibroblasts and capillary endothelial cells, which are early signs of wound healing. One example of this method, using the peptide KRFK (SEQ ID NO:5), is provided in the Examples.

10

In the method of enhancing wound healing, the activating peptide can be selected from the group consisting of: KRFK (SEQ ID NO:5), HRFK (SEQ ID NO:6), RKPK (SEQ ID NO:7), QRFK (SEQ ID NO:8), KRFKQDGG (SEQ ID NO:9), RWRPWTAWSE (SEQ ID NO:10), TAYRWRLSHRPKTGIRV (SEQ ID NO:11), KRFKQDGGGASHPASS (SEQ ID NO:12), KRFKQDGGGASHASP (SEQ ID NO:13), KRFKQDGGWSHWSP (SEQ ID NO:14), KRFKQDGGWSHWSPWSS (SEQ ID NO:15), KRFKQDGGWSHW (SEQ ID NO:16) and KRFKQDGGWWSP (SEQ ID NO:17) or can consist of the amino acid sequence RFK (SEQ ID NO:18). Such sequences are determined to be activating sequences which enhance wound healing by screening for enhanced wound healing in rat models of wound healing as described in the Examples.

20

Because TGF- β plays a role in the development of fibrosis, the present invention also provides a method of preventing fibrosis stimulated by TGF- β in pathology by administering to a site of potential fibrosis an amount of a purified inhibiting peptide from TSP effective to inhibit conversion of latent TGF- β to active TGF- β , resulting in reduced fibrosis. The inhibiting peptides can include those described herein. As used herein, "fibrosis" means the abnormal formation of fibrous tissue (60,64). "Reduced fibrosis," as used herein, is defined as the statistically significant reduction in the level of abnormal formation of fibrous tissue as determined by histological analysis, tensile strength and total protein and collagen content in a

25

30

wound treated with an inhibitory peptide from TSP as compared to the level of abnormal formation of fibrous tissue in a similar untreated wound or a similar wound treated with a peptide having no activity under conditions such that fibrosis is expected to develop. One example of this method, using the TSP peptide GGWSHW (SEQ ID NO:3), is provided in the Examples.

In the method of preventing fibrosis stimulated by TGF- β in pathology, the inhibiting peptide can also be selected from the group consisting of: WNDWI (SEQ ID NO:19), WSSWS (SEQ ID NO:20), LSKL (SEQ ID NO:21), AAWSHW (SEQ ID NO:22), DGWSPW (SEQ ID NO:23), GGWGPW (SEQ ID NO:24), WSPWS (SEQ ID NO:25), GWSHW (SEQ ID NO:26) and WSHWS (SEQ ID NO:27). Such sequences are determined to be inhibiting sequences which prevent fibrosis by screening for prevention of fibrosis in rat models of fibrosis formation as described in the Examples.

A method is also provided for preventing excessive fibrosis stimulated by TGF- β in certain pathologies by administering to a site of potential fibrosis an amount of a ligand specific for TSP, effective to bind TSP, thereby inhibiting the stimulation of TGF- β , resulting in reduced fibrosis.

Active TGF- β inhibits the proliferation of endothelial and epithelial cells. Thus, in another embodiment, the present invention provides a method of blocking TGF- β -mediated inhibition of endothelial or epithelial cell proliferation, comprising contacting the cells with an amount of TSP or a purified inhibiting peptide from TSP effective to inhibit conversion of latent TGF- β to active TGF- β , resulting in proliferation of the cells. As used herein, "proliferation" means an increase in the number of cells.

Also provided is a method of blocking TGF- β -mediated inhibition of endothelial or epithelial cell proliferation, comprising contacting the cells with a ligand

specific for TSP effective to bind TSP and inhibit activation of TGF- β , resulting in proliferation of the cells.

In the methods of blocking TGF- β -mediated inhibition of cell proliferation, the cells can be arterial endothelial cells. Other cells that can proliferate in response to these methods are capillary endothelial cells. The inhibiting peptide can be selected from the group consisting of: WNDWI (SEQ ID NO:19), WSSWS (SEQ ID NO:20), LSKL (SEQ ID NO:21), AAWSHW (SEQ ID NO:22), DGWSPW (SEQ ID NO:23), GGWGPW (SEQ ID NO:24), WSPWS (SEQ ID NO:25), GWSHW (SEQ ID NO:26) and WSHWS (SEQ ID NO:27) or can consist of the amino acid sequence GGWSHW (SEQ ID NO:3). Such sequences are determined to be inhibiting sequences by screening for TGF- β -mediated inhibition of cell proliferation, as described in the Examples.

The invention provides TGF- β activating and inhibiting peptides derived from the functional sequences of TSP. The present invention also provides a purified peptide having 3 to 30 amino acids, wherein the peptide comprises a subsequence $R_1-X_1-X_2-X_3-R_2$, wherein X_1 is selected from the group consisting of Arg and Lys, X_2 is selected from the group consisting of Pro and Phe, X_3 is selected from the group consisting of Lys and Arg, R_1 is H_2 , acyl, or a peptide from 1 to 26 amino acids, R_2 is H, NH_2 , or a peptide of from 1 to 26 amino acids, and wherein the peptide converts latent TGF- β to active TGF- β .

The purified peptide can be selected from the group consisting of: RFK (SEQ ID NO:18) KRFK (SEQ ID NO:5), HRFK (SEQ ID NO:6), RKPK (SEQ ID NO:7), QRFK (SEQ ID NO:8), KRFKQDGG (SEQ ID NO:9), TAYRWRLSHRPKTGIRV (SEQ ID NO:11), and KRFKQDGGASHASPASS (SEQ ID NO:12) or can consist of the amino acid sequence RWRPWTAWSE (SEQ ID NO:10).

The purified peptide can be conjugated to a water soluble polymer using standard protein conjugation protocols (61). For example, suitable water soluble polymers include polysucrose, dextran, polyethylene glycol and polyvinyl alcohol.

- 5 The purified peptide can also be selected from the group consisting of partial and full retro-inverso peptide sequences. As used herein, "partial and full retro-inverso peptide sequences" means peptide sequences, determined to be either activating or inhibiting, which comprise some D-amino acids (partial) or consist entirely of D-amino acids (full), gem-diaminoalkyl residues, and alkylmalohyl residues.
- 10 These can have unmodified termini, or can include appropriate alkyl, acyl, or amine substitutions to modify the charge of the terminal amino acid residues.

The present invention further provides purified peptides consisting of the amino acid sequences LSKL (SEQ ID NO:21) and acetyl- WHSWAA-NH₂ (SEQ ID NO:28), and their partial and full retro-inverso peptide sequences.

15

Due to the relatively short half-life of peptides *in vivo*, the effects of modified peptides with longer half-lives can be examined. For example, the retro-inverso amino acid sequences (i.e., composed of D-amino acids) of the peptides described herein, such as the KRFKQDGGWSHWSPWSS (SEQ ID NO:15) and GGWSHW (SEQ ID NO:3) peptides, can be employed as described. These are expected to have a longer half life, because D-amino acids cannot be metabolized by cells as can naturally occurring L-forms of amino acids in proteins (65). Such retro-inverso peptides can be synthesized by standard peptide synthesis methods using commercially available D-amino acids (74). Peptide mimetics may be employed as substitutes for the natural peptide sequences based on established methods (75).

20

25

The described peptides can be applied in *in vivo* models to verify their modulation of TGF- β -mediated effects of wound healing and fibrosis formation. For example, rat models of wound healing can be used to evaluate the effectiveness of KRFK (SEQ ID NO:5) in stimulating wound healing in comparison to active TGF- β

30

(62,63). An inactive peptide can be used as a negative control (e.g., TRIR (SEQ ID NO:30), KRAK (SEQ ID NO:35)).

The GGWSHW (SEQ ID NO:3) peptide or other inhibiting peptides
5 provided herein can also be examined for any effect on inhibiting wound healing by blocking TGF- β activation or for any effect in keloid formation. Inactive analogues of this peptide can be used as negative controls.

The *in vivo* protocol of Sporn *et al.* (62) can be used to determine the
10 relative effectiveness of the TSP or activating peptides described herein on wound healing. For example, 2 cm by 1 cm wire mesh wound chambers can be implanted in the backs of rats. After a wound healing response is initiated (day 4), rats can be given daily injections of either 1000 ng TGF- β , 100-1000nM of activating peptides, 100-1000nM TSP, 1000 ng albumin or vehicle control per injection site at the wound
15 site. On day 9, the animals can be sacrificed and tissues in the wound chambers can be examined histologically, assayed for total protein and collagen content (by measurement of hydroxy-proline content) and relative levels of TGF- β in the wound tissue can be examined by immunohistochemical techniques.

20 Alternately, a rat model of incisional wound healing as described by Cromack *et al.* (63), can be used. In this system, a 6 cm linear incision can be made on the dorsal skin of a rat, the wound can be coapted with surgical clamps and 100-1,000nM of TSP or 100-1000nM of activating peptides can be injected at the wound site in 3% methylcellulose as a vehicle. After 7-10 days, the wound strips can be
25 harvested and evaluated for tensile strength using a tensiometer and for histological analysis as described herein.

The above-described protocols can be applied to humans, because wound healing and fibrosis formation in rats, rabbits and pigs are commonly used as
30 models for the study of wound healing and fibrosis formation in humans. (66-69).

In a clinical application, 1 μ g to 100 mg of TSP or the activating peptides from TSP can be used to impregnate bandages or as part of an ointment to be applied to wound areas for the purpose of enhancing wound healing or preventing fibrosis. A skilled clinician would be able to determine, more specifically, the amount of peptides and length of treatment necessary to enhance wound healing or inhibit fibrosis.

The ligands, TSP or peptides from TSP may be administered parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, topically, transdermally, or the like, although topical administration is typically preferred. The exact amount of such compounds required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the wound or disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact amount. However, an appropriate amount may be determined by one of ordinary skill in the art using methods well known in the art.

For topical administration, the compounds of the present invention can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example powders, liquids, suspension, lotions, creams, gels or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include, as noted above, an effective amount of the selected compound in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected compound without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

Parenteral administration, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Parenteral administration can also employ the use of a slow release or sustained release system, such that a constant level of dosage is maintained (See, for example, U.S. Patent No. 3,710,795).

Utility

The present invention also provides a bioassay for screening substances for their ability to modulate the activity of TSP. For example, the present invention provides a bioassay for screening substances for their ability to enhance the activity of TSP, for example, for use in therapies to promote wound healing. In another example, the present invention provides a bioassay for screening substances for their ability to inhibit the activity of TSP, for example, for use in therapies for prevention of fibrosis. Briefly, these bioassays can be performed *in vitro* by administering a substance to NRK cells with TSP or peptides from TSP and latent TGF- β and assaying for soft agar colony formation as described in the Examples. Alternatively, these bioassays can be performed *in vitro* by administering a substance to BAE cells and measuring cell proliferation as described in the Examples. The current use of such screening methods is set forth in the Examples, which show that the peptide KRFK (SEQ ID NO:5) activates TGF- β and the peptide GGWSHW (SEQ ID NO:3) inhibits TSP-mediated activation of latent TGF- β . *In vivo*, these bioassays can be performed by administering substances to the wound chambers and wound sites as described herein to screen for substances which play a role in wound healing and fibrosis.

The present invention further provides peptides which activate and inhibit TGF- β , which can be used as controls in *in vitro* bioassays for screening substances for their ability to modulate the activity of TGF- β . For example, the substances and TGF- β can be administered to NRK cells which can then be assayed for soft agar colony formation as described in the Examples. Activating or inhibiting peptides can be administered to NRK cells which can then be assayed for soft agar

colony formation as positive controls for TGF- β activation and inhibition. These activating and inhibiting peptides can also be used as controls in *in vivo* bioassays for screening substances for their ability to modulate the activity of TGF- β . For example, substances can be applied to the wounds and sites of potential fibrosis in the assays described in the Examples and evaluated for their ability to enhance wound healing and reduce fibrosis. The activating and inhibiting peptides can be used as controls in the described Examples.

The invention provides a method of generating a purified antibody specifically reactive with TSP or a peptide of the invention. The antibodies made can be used to detect the presence of TSP. Antibodies can be made as described in the art (61). Briefly, purified TSP, purified peptide alone or peptide conjugated to a carrier protein can be injected into an animal in an amount and in intervals sufficient to elicit an immune response. Antibodies can either be purified directly, or, for monoclonal antibodies, spleen cells can be obtained from the animal. The cells are then fused with an immortal cell line and screened for antibody secretion.

The following examples are intended to illustrate, but not limit, the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may be alternatively employed.

The present invention is more particularly described in the following examples which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art.

EXAMPLES

Thrombospondin Purification

TSP was purified as previously described (34). Briefly, 8-10 units of fresh human platelets were purchased from the Birmingham American Red Cross and washed with Hepes wash buffer (10% ACD, 0.05M Hepes, 0.15M NaCl, and 5mM

dextrose), pH 7.6. The platelets were thrombin-stimulated and the platelet releasate was applied to a heparin-SepharoseTM CL-6B (Pharmacia, Piscataway, New Jersey) affinity column pre-equilibrated with TBS-C (0.01M Tris-HCl, 0.15M NaCl, 0.1mM CaCl, pH 7.4). The bound TSP was eluted with 0.55M NaCl/ TBS with 1mM CaCl and applied to an A0.5M gel filtration column (Bio-Rad, Richmond, California) pre-equilibrated with TBS-C, pH 11, to remove associated TGF- β , yielding TSP stripped of TGF- β activity (sTSP). Purity was assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue or silver staining. No contaminating TGF- β activity was found associated with sTSP in normal rat kidney (NRK) soft agar colony formation assays.

Cells

Bovine aortic endothelial (BAE) cells were isolated from aortas obtained at a local abattoir, and were characterized by the uptake of acetylated low density lipoproteins (Dil-AcLDL) and staining for Factor VIII antigen. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Cell-Gro, Mediatech, Herndon, VA) supplemented with 4.5 g/L glucose, 2mM glutamine, and 20% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT) as previously described (33). NRK clone 49F cells (ATCC Accession No. CRL 1570) were cultured in DMEM supplemented with 4.5 g/L glucose, 2mM glutamine, and 10% calf serum (Hyclone Laboratories, Logan, UT) as described (1). Calf serum was tested and chosen for low levels of active TGF- β . Mink lung epithelial cells (ATCC Accession No. CCL 64) (Mv 1 Lu) were cultured in minimum Eagle's medium (MEM; Cell-Gro, Mediatech, Herndon, VA) supplemented with 4.5g/L glucose, 2mM glutamine, and 10% FBS. Stocks were cultured in F-12 (Cell-Gro, Mediatech, Herndon, VA) supplemented with 10% FBS. All cells tested negative for *Mycoplasma* contamination.

Antibodies

Mouse anti-TSP 133 was raised against sTSP and developed at the Monoclonal Antibody Core facility at the University of Alabama at Birmingham. This antibody is a IgG_{2b} which recognizes the 50kDa chymotryptic fragment of sTSP by

Western blotting. Mab TSP-B7 ascites was raised against human platelet releasate and is specific for TSP (11) (Sigma Chemical, St. Louis, Missouri).

A chicken anti-TGF- β antibody was purchased from Oncomembrane, Seattle, Washington and a mouse monoclonal anti-TGF- β antibody was purchased from Genzyme, Cambridge, Massachusetts. Anti-vitronectin monoclonal and polyclonal antibodies were purchased from Telios, San Diego, California. A polyclonal anti-platelet factor 4 antibody was purchased from Atlantic Antibodies, Scarborough, ME. Mouse monoclonal anti-basic fibroblast growth factor (bFGF) was obtained from Upstate Biotech. Inc., Lake Placid, New York.

Peptide Synthesis

Peptides corresponding to sequences of human TSP1 as deduced from a cDNA sequence for TSP1 (70), were synthesized on a Model 9600 peptide synthesizer (Biosearch, San Rafael, California) using standard Merifield solid phase synthesis protocols and t-Boc chemistry (56,57,71). Peptides were analyzed for purity by reverse-phase HPLC. Larger peptides were also characterized by amino acid sequencing.

20 Production of the Second Type 1 Repeat Fusion Construct

The second type 1 repeat of TSP1 corresponding to exon 9 was produced by making PCR primers which correspond to the intron-exon boundaries of exons 8-9 and 9-10. The cDNA strands were expanded by polymerase chain reaction (PCR) and expressed in *E. coli* cells using glutathione-S-transferase. The expressed proteins were characterized by sequence analysis and gel electrophoresis.

NRK Colony Formation in Soft Agar

TGF- β activity was assayed by determining colony formation of NRK cells in soft agar assays as described (34), except assays were performed in 24 well tissue culture plates. Briefly, 5% Noble agar (Difco, Detroit, Michigan) was diluted ten-fold in 10% calf serum/DMEM and 0.5 ml of this 0.5% agar dilution was added

per well to a 24 well tissue culture plate as a base layer and allowed to harden. A 0.2 ml sample containing 5 ng epidermal growth factor (EGF) was combined with 0.6 ml 0.5% agar and 0.2 ml (2×10^3) of an NRK cell suspension in 10% calf serum/DMEM. A 0.5 ml aliquot of this 0.3% agar-sample solution was added to the cooled agar base layer and the plates were incubated for seven days at 37°C, 5% CO₂. Colonies greater than 62 µm in diameter (>8-10 cells) were counted. Experiments were performed in triplicate.

BAE Cell Proliferation Assays

BAE cells were plated at 5000 cells per well in 1 ml of DMEM with 20% FBS in 24 well tissue culture plates and incubated overnight at 37°C, 5% CO₂. The cells were rinsed once in serum-free DMEM. Test samples in 0.5 ml 2.5% FBS DMEM were added to each well in triplicate (day 0). On day 2, cells received fresh aliquots of test sample in 0.5 ml without removing the original medium (to give a final volume of 1 ml). Cells were grown for another two days, then culture medium was removed and cells were trypsinized with 0.5 ml trypsin-EDTA (Gibco, Grand Island, NY) and harvested. The number of harvested cells was determined using a model ZM Coulter Counter (Coulter Electronics, Hialeah, FL).

Preparation of BAE Conditioned Medium

BAEs were plated at a density of 100,000 cells in a 25 cm² flask in 20% or 0.2% FBS/DMEM and incubated overnight at 37°C, 5% CO₂. This density was determined by comparing the ability of sTSP to activate latent TGF-β in sparse, sub-confluent, and confluent BAE cultures. This cell density showed the greatest difference in levels of active TGF-β between control and TSP-treated medium. Flasks were rinsed once with 2 ml serum-free DMEM and then test samples were added in 2.5 ml of DMEM with either 0.2% or 20% FBS. The flasks were incubated for additional times at 37°C, 5% CO₂. Conditioned medium was collected, centrifuged at 1200 rpm for five minutes to remove cellular debris, and stored at 4°C in polypropylene tubes for no more than 3 days before testing in NRK soft agar assay to determine TGF-β activity.

Activation of Purified Latent Recombinant TGF- β by sTSP or Peptides

Various concentrations of sTSP or the synthesized peptides were incubated with 2nM (200 ng/ml) purified small latent recombinant TGF- β (LTGF- β) (Bristol-Myers Squibb, Seattle, WA) in a final volume of 0.5 ml phosphate buffered saline (PBS) for one hour at 37°C. As a positive control, 4mM HCL was used for TGF- β activation. PBS was added to cells to establish a baseline for cell proliferation. Bovine serum albumin (BSA) (0.1%) was added to all of the samples to reduce non-specific binding of TGF- β to the tube. Samples were tested in soft agar NRK colony formation assays for TGF- β activity.

10

Effect of Protease Inhibitors on the Sensitivity of sTSP-Mediated Stimulation of TGF- β Activity

BAE cells were seeded at 1×10^5 cells/ 25 cm² flask in DMEM with 20% FBS and incubated overnight. Cells were washed with DMEM, and one of the following protease inhibitors: ϵ -aminocaproic acid (EACA, 0.3mM), aprotinin (6mM), and alpha2-antiplasmin(0.6uM) was added, with 1 μ g sTSP (0.4 ug/ml), to each flask in DMEM with either 2.5 ml 0.2% or 20% FBS and then incubated with cells an additional 48 hrs. Aliquots of conditioned medium were tested in NRK colony forming soft agar assays to determine TGF- β activity. Recombinant TGF- β (5 ng/ml) was also incubated with the inhibitors and assayed for colony forming activity. Inhibitors alone were also added to the conditioned medium.

15
20**Effect of sTSP on Mature rTGF- β Activity and Stimulation of TGF- β Activity in FBS**

The NRK colony forming assay was performed as described herein. All samples contained 5 ng/ml EGF in 10% calf serum/DMEM, except samples in which EGF was in 0.2% FBS. Stripped TSP (1 μ g/ml) was preincubated with 1 ng/ml rTGF- β for two hrs at 37°C and compared for relative activity versus 1 ng/ml rTGF- β or 1 μ g/ml sTSP. Anti-sTSP antibody Mab133 (10 μ g/ml) was pre-incubated with recombinant TGF- β (rTGF- β) (Bristol Myers Squibb, Seattle, WA) for two hrs at 37°C before addition to NRK cells in soft agar. sTSP (3 μ g/ml) was also incubated

25
30

with 0.2% FBS for two hrs at 37°C and tested for relative activity versus sTSP (3 µg/ml) or 0.2% FBS. All samples were tested in the NRK soft agar for seven days at 37°C, 5% CO₂.

5 TSP Stripped of TGF-β Activity Inhibits the Growth of BAE Cells

To examine whether TSP stripped of associated TGF-β (sTSP) activity inhibited BAE growth, cell proliferation assays were performed using sTSP. BAE cells were exposed to increasing concentrations of either native TSP (TGF-β activity associated with TSP), or sTSP (no associated TGF-β activity) in medium

- 10 supplemented with 2.5% FBS for a period of four days, at which time cell number was determined. Native TSP and sTSP significantly inhibited the proliferation of BAE cells as compared to 2.5% FBS alone. Furthermore, the dose response curves were nearly identical for native and sTSPs. No significant cell death was observed. The inhibition of BAE proliferation by TSP was concentration dependent with 1 µg/ml sTSP
- 15 inhibiting 75% of growth. Cells grown in the presence of sTSP assumed a more elongated, fibroblastic shape and had prominent nucleoli as compared to the polygonal cells in the 2.5% FBS medium control. Similarly, TGF-β treated cells were elongated with numerous processes and prominent nucleoli.

- 20 A neutralizing antibody to TGF-β reversed the growth inhibitory effects of sTSP by 42%. Addition of the neutralizing antibody against TGF-β to wells containing sTSP also caused a partial reversion to a smaller, more polygonal cell, characteristic of normal BAE cells. Similar results were obtained with both mouse and chick anti-TGF-β antibodies. In contrast, a polyclonal antibody and various
- 25 monoclonal antibodies specific for native TSP were not able to neutralize sTSP-mediated growth-inhibition. Antibodies alone did not affect cell growth. Thus, growth inhibition of BAE cells by TSP stripped of associated TGF-β activity may be at least partially due to a TGF-β-dependent component.

Stripped TSP Activates TGF- β in BAE Conditioned Media (CM)

Since sTSP-mediated BAE growth inhibition is partially TGF- β dependent, it is possible that sTSP incubation with BAE cells is causing activation of endogenous latent TGF- β . TGF- β is secreted from endothelial cells as an inactive molecule (18) and it is not entirely clear how endothelial cell latent TGF- β is activated. In order to test the hypothesis that sTSP activates latent TGF- β secreted by endothelial cells, sTSP was added to BAE cells in DMEM with 0.2% FBS for 0-48 hrs.

10 Aliquots of the conditioned medium were tested in NRK colony forming soft agar assays for the presence of TGF- β activity. Stripped TSP at 0.4 $\mu\text{g/ml}$ (0.9nM) increased colony forming activity in the conditioned media by 2-3 fold as compared to conditioned medium alone. Increases in TGF- β activity were observed as early as 15 minutes after addition of sTSP to cells and persisted above control levels for at least 48 hrs. Similar levels of activation were observed when cells were conditioned in media where serum levels were raised from 0.2% to 20%, suggesting that sTSP-mediated stimulation of TGF- β activity is independent of serum factors.

Stimulation of TGF- β Activity is Dependent on sTSP Concentration.

20 To assess whether the stimulation of TGF- β activity in BAE conditioned media was dependent on the concentration of sTSP present, varying doses of sTSP ranging from 10 ng to 10 μg were added to BAE cells in 2.5 ml of medium. Concentrations of sTSP between 40-400 ng/ml (100-1000 ng added) were effective at stimulating NRK colony formation in soft agar. The maximal response was repeatedly observed with 1 μg sTSP/25 cm^2 flask (0.4 $\mu\text{g/ml}$, or 0.9 nM). When compared rTGF- β , the level of maximal NRK colony formation induced by sTSP correlated to approximately 0.1 ng/ml of TGF- β activity.

Stripped TSP Does Not Affect the Activity of Mature rTGF- β or Stimulate TGF- β Activity in FBS

To rule out that the increase in TGF- β activity in the NRK soft agar assays was due to sTSP acting at the level of the NRK cells, experiments were done to
5 determine whether sTSP affected mature rTGF- β activity and whether anti-sTSP antibody 133, which inhibits sTSP stimulation of TGF- β activity in the conditioned medium, affected TGF- β activity in the NRK assay. There was no modulation of rTGF- β activity by either sTSP or anti-TSP antibodies, nor did sTSP by itself stimulate colony formation. Stripped TSP also did not activate the latent TGF- β present in
10 0.2% FBS.

Stimulation of TGF- β Activity in BAE Conditioned Media is Specific for sTSP

Other extracellular matrix proteins were tested for their ability to activate endothelial cell secreted latent TGF- β . Equimolar amounts of tenascin,
15 fibronectin, BSA, or laminin did not stimulate TGF- β activation. Basic FGF, in contrast to a previous report (13), did not stimulate increased TGF- β activity in our system. These results show that stimulation of TGF- β activity in BAE conditioned medium is not a general property of extracellular matrix molecules, including TGF- β -binding molecules such as fibronectin, and, therefore, is a specific property of
20 sTSP.

Antibodies to sTSP Inhibit Stimulation of TGF- β Activity by sTSP.

To eliminate the possibility that the observed increase in TGF- β activity was due to potential components associated with sTSP, an attempt was made to block
25 stimulation with antibodies to TSP. Monoclonal antibody 133 ascites, which recognizes an epitope in the 50kDa chymotryptic fragment of sTSP, completely inhibited the stimulation of TGF- β activity by sTSP. Mab TSP-B7 ascites, which is specific for the 70kDa core of platelet TSP (11) also blocked this effect of sTSP. However, another monoclonal antibody which recognizes an epitope in the 70kDa
30 fragment of native TSP only inhibited sTSP activation of latent TGF- β by 32%.

Antibodies alone had no effect on these assays and did not interfere with the ability of rTGF- β to form colonies in soft agar.

Colony formation was also TGF- β dependent, since a polyclonal
5 chicken anti-TGF- β antibody and a monoclonal mouse anti-TGF- β neutralizing
antibody completely inhibited colony formation. These results showed that the factor
activated by sTSP in BAE conditioned medium is TGF- β .

In contrast, antibodies to vitronectin (both monoclonal and polyclonal),
10 platelet factor-4, bFGF, and control ascites, did not inhibit the stimulation by sTSP.
These data showed that increases in TGF- β activity observed in the NRK soft agar
assays were not due to the presence of commonly associated matrix and platelet
proteins, but were dependent on sTSP and TGF- β .

15 **Stripped TSP Stimulation of TGF- β Activity in BAE Conditioned Medium
Occurs Independently of Binding to the Cell Surface.**

A proposed mechanism of latent TGF- β activation *in vivo* is through
binding to and internalization of latent TGF- β by mannose-6-phosphate receptors and
subsequent processing in acidifying vesicles or processing by plasmin at the cell surface
20 (12,20,21). Experiments were performed to determine whether sTSP requires
interactions with cell surface molecules in order to activate latent TGF- β . After
incubating BAE cells in DMEM with 0.2% FBS overnight, the medium was removed
from the culture flasks and incubated in polypropylene tubes in the presence or absence
of sTSP (0.4 μ g/ml) for the indicated times. This was done in direct comparison with
25 sTSP incubated in the presence of cells. Aliquots of the conditioned medium were
then tested in NRK colony forming soft agar assays for sTSP-mediated activation of
TGF- β . These data showed that sTSP was able to activate TGF- β in the absence of
cells to a similar extent and with similar kinetics to sTSP incubated in the presence of
cells. Cell-conditioned medium incubated with sTSP in the absence of cells
30 demonstrated increased TGF- β activity as early as 15 min after addition of sTSP.
Maximal levels were reached by two hrs and persisted above baseline for at least 48

hrs. Thus, in contrast to previously reported mechanisms of activation, TSP-mediated activation of latent TGF- β does not require interactions with cell surface molecules.

5 Stripped-TSP Mediated Stimulation of TGF- β Activity is Insensitive to Serine Protease Inhibitors.

Previous studies have shown that plasmin can activate latent TGF- β *in vitro* (22,23). In co-cultures of endothelial and smooth muscle cells, plasmin levels have been shown to be upregulated, thus, activating latent TGF- β (40,41). A common
10 motif is the involvement of a serine protease in the activation of latent TGF- β . Therefore, the effects of different serine protease inhibitors on the activation of TGF- β by sTSP in BAE conditioned medium were tested. BAE cells were incubated with sTSP (0.4 μ g/ml) in addition to either ϵ -aminocaproic acid (EACA, 0.3mM), aprotinin (6mM), or alpha2-antiplasmin (0.6uM). The concentrations of these inhibitors were
15 chosen based on previous studies (40) and dose response assays. These inhibitors did not inhibit sTSP-mediated activation of TGF- β and had no effect on rTGF- β activity in soft agar assay. Inhibitors alone were also added to the conditioned medium and had no effect on the assay.

20 Due to evidence that TSP can interact with these serine proteases (7), sTSP was also tested for associated plasmin and thrombin activity using enzyme assays measuring generation of chromogens from specific substrates (Boehringer-Mannheim, Indianapolis, IN). No associated plasmin or thrombin activity was detected in sTSP and there was no generation of plasmin activity in sTSP-conditioned medium as
25 compared to control conditioned medium.

These data showed that, in contrast to activation of endothelial cell-derived latent TGF- β by bFGF or in co-culture systems, latent TGF- β activation by sTSP does not involve serine proteases.

Stripped TSP Can Activate Purified Recombinant Latent TGF- β (LTGF- β)

To determine if sTSP was activating latent TGF- β without the involvement of cell-secreted factors, sTSP was incubated with LTGF- β for two hrs and then assayed for TGF- β activity. Stripped TSP was able to activate LTGF- β at
5 both 37°C and 4°C. Stripped TSP at a concentration of 13nM could activate approximately half of the acid-activatable LTGF- β . These results showed that sTSP was able to activate LTGF- β directly, without the involvement of cell-secreted factors such as proteases.

10 A Unique Peptide in the Second Type 1 Repeat Activates Latent TGF- β

To determine if TGF- β activation was due to either of the type 1 consensus sequences, CSVTCG (SEQ ID NO:1) and WSXW (SEQ ID NO:2), the peptides, VTCGGGVQKRSRL (SEQ ID NO:29) and KRFKQDGGWSHWSPWSS (SEQ ID NO:15), were constructed and analyzed to determine the effect of these
15 sequences on activation of TGF- β .

Latent TGF- β was incubated with equimolar concentrations of sTSP or the above peptides and activation of TGF- β was assayed by soft agar NRK colony formation. As shown in Table I, the addition of TGF- β incubated with 11nM sTSP
20 increased NRK colony formation approximately twofold over the PBS baseline control. The VTCGGGVQKRSRL (SEQ ID NO:29) peptide failed to activate latent TGF- β when tested at concentrations up to 11 μ M. The KRFKQDGGWSHWSPWSS (SEQ ID NO:15) peptide increased colony formation to levels equal to those observed with sTSP. These data indicated that the mechanism by which TSP activates latent
25 TGF- β is independent of the CSVTCG (SEQ ID NO:1) cell adhesion motif, and is associated with the KRFKQDGGWSHWSPWSS (SEQ ID NO:15) peptide.

The amino acid sequence, arginine-phenylalanine-lysine activates latent TGF- β

To further localize which region within the
30 KRFKQDGGWSHWSPWSS (SEQ ID NO:15) sequence activates latent TGF- β , the following peptides, containing deletions at the carboxy-terminal of the peptide, were

constructed: KRFKQDGGWSHWSP (SEQ ID NO:14), KRFKQDGGWSHW (SEQ ID NO:16), KRFKQDGGWWSP (SEQ ID NO:17), KRFKQDGG (SEQ ID NO:9), KRFK (SEQ ID NO:5) and RFK (SEQ ID NO:18). Recombinant latent TGF β was incubated with equimolar concentrations of the peptides, sTSP or the

5 KRFKQDGGWSHWSPWSS (SEQ ID NO:15) peptide and tested for TGF- β activity. As shown in Table I, all peptides containing the amino-terminal basic residues of KRFKQDGGWSHWSPWSS (SEQ ID NO:15) activated latent TGF- β to levels comparable to sTSP. The tripeptide, RFK (SEQ ID NO:18), represented the minimal sequence required to activate TGF- β . Deletion of the WSHW (SEQ ID NO:2)

10 sequence from the peptide failed to diminish the TGF- β activating potential, which indicates that the consensus sequence WSXW may have no direct role in the activation of latent TGF- β by TSP.

These data were consistent with the results of experiments

15 demonstrating the inability of fusion constructs of the amino acids encoded by exon 9 to activate latent TGF- β . Exon 9 encodes amino acid residues Lys 415 through Ile 473 and contains the entire second type 1 repeat sequence of TSP1. However, the fusion protein produced lacks the KRF sequence. These data provided further support that the sequence (K)RFK is required for activation of latent TGF- β .

20

Certain Amino Acids Within the KRFK Sequence are Necessary for Activity

To determine which amino acids in the (K)RFK sequence are necessary for activation of latent TGF- β , peptides containing amino acid substitutions were synthesized and tested for their ability to activate latent TGF- β . The results of this

25 experiment are shown in Table II.

As shown in Table II, the peptide, KRFK (SEQ ID NO:5), activated latent TGF- β twofold over the baseline control. The peptide, TRIR (SEQ ID NO:30) (the corresponding sequence in the second type 1 repeat in TSP2), did not activate

30 latent TGF- β , indicating that the activation of TGF- β is a function specific to TSP1.

The substitution of Lys 412 with amine group-containing residues, Gln (QRFK (SEQ ID NO:8)) or His (HRFK (SEQ ID NO:6)), did not diminish activity. Substitution of Lys 412 with Ala (ARFK (SEQ ID NO:31)), which lacks an amine group, abrogated activity (Table II).

5

Arg 413 is also important for activity. Arg was replaced with Lys (KKFK (SEQ ID NO:32)) without diminishing activity, but substitution with a Gln, which lacks a positively charged amine group, (KQFK (SEQ ID NO:33)) abolished activity. This suggests that a positively charged amine or guanidino group in position 10 413 is necessary for activity. Similarly, substitution of Lys 415 with Gln (KRFQ (SEQ ID NO:34)) resulted in loss of activity.

As further demonstrated in Table II, Phe 414 was required for activity. Substituting Ala (KRAK (SEQ ID NO:35)) for Phe 414 resulted in loss of activity. 15 Other aromatic residues such as Tyr (KRYK (SEQ ID NO:36)) or Trp (KRWK (SEQ ID NO:37)) cannot substitute for Phe 414, because these amino acid substitutions inactivated the peptide. These experiments demonstrated a specific requirement for Phe in this position.

20 The tripeptide, RFK (SEQ ID NO:18) activated latent TGF- β 2.5 fold over baseline controls. However, substitution of Lys 415 with Arg (RFR (SEQ ID NO:43)) abolished activity, as did replacement of both Phe 414 and Lys 415 with Trp and Arg (RWR (SEQ ID NO:44)), respectively (Table II).

25 In addition, a peptide with an inverted sequence of KRFKQDGGWSHWSPWSS (SEQ ID NO:15), composed of D-amino acids and modified with an N-terminal acetyl and a C-terminal amide, was synthesized to obtain a peptide with a longer physiologic half-life. This retro-inverso peptide activated latent TGF- β at equimolar concentrations of sTSP. These data indicated that this peptide 30 might have more sustained TGF- β modulating activity under physiologic (*in vivo*) conditions than the standard peptide.

The peptides listed in Table III either activate or inhibit activation of latent TGF- β as determined by analysis using the experimental protocols described in the Examples herein.

5 Activation of latent TGF- β by (K)RFK is Independent of Heparin-binding Activity

BBxB is a well known heparin-binding motif wherein B represents a basic amino acid (K,R,H) and x is any amino acid (72). The KRFKQDGGWSHWSPWSS (SEQ ID NO:15) peptide of TSP has been shown to
10 bind heparin, but this activity is localized to the WSHW (SEQ ID NO:4) region of the peptide (56,71). To examine whether activation of latent TGF- β by TSP was associated with the BBxB motif, TSP peptide Hep II, ASLRQMKKTRGTLALERKDHS (SEQ ID NO:38) (residues 74-95), which contains the BBxB motif and binds heparin (73), and a second heparin-binding TSP
15 peptide lacking this consensus motif, Hep I, ELTGAARKGSGRRLVKGPD (amino acids 17-35) (SEQ ID NO:39), were analyzed for TGF- β activating capability. Neither Hep I nor Hep II activated latent TGF- β when assayed at concentrations up to 11 μ M. These results demonstrated that activation of latent TGF- β is a specific function of the KRFK (SEQ ID NO:5) sequence of TSP and is not dependent upon the
20 BBxB motif.

Because heparin is an anionic polysaccharide, experiments were conducted to determine if heparin blocked TGF- β activation by either sTSP or the peptides. It was found to have no effect. Based on these results, it was determined that
25 the binding/activation of latent TGF- β by sTSP or the peptides is not mediated via carbohydrate interactions.

The RFK Sequence Present in other Proteins does not have TGF- β Activating Function

30 Calcineurin (Sigma Chemicals, St. Louis, Missouri) and BSA, both of which contain the RFK (SEQ ID NO:5) sequence, were examined to determine if

activation of latent TGF- β by this sequence is a function of this peptide sequence in other proteins. Latent TGF- β was incubated with equimolar amounts of sTSP, calcineurin, or BSA and assayed for activation. As determined by soft agar NRK colony formation, only sTSP activated TGF- β , indicating that the RFK (SEQ ID NO:5) sequence as it is presented within the calcineurin (KRFK (SEQ ID NO:5)) and BSA (HRFK (SEQ ID NO:6)) proteins lacks the TGF- β activity function.

Modification of the Trp Residues in the Larger Peptides Results in a Loss of Activity

The above results showed that the sequence (K)RFK is directly responsible for the activation of latent TGF- β by sTSP. To determine whether other residues in the larger peptides are important for TGF- β activation, amino acid residues Trp 420, Trp 423 and Trp 426 were all substituted to Ala residues in the KRFKQDGGWSHWSPWSS (SEQ ID NO:15) peptide and KRFKQDGGWSHWSP (SEQ ID NO:14) peptide to produce the peptides KRFKQDGGASHASPASS (SEQ ID NO:12) and KRFKQDGGASHASP (SEQ ID NO:13) and each of these was tested for TGF- β activating potential. Latent TGF- β was incubated with increasing concentrations of each of the four peptides or TSP and assayed for NRK colony forming activity. The substitution of Trp residues with Ala residues abolished the TGF- β activating function of the Trp-containing peptides at the nanomolar concentrations previously shown to be effective for the unmodified peptides or sTSP. However, peptides lacking the Trp residues activated latent TGF- β when applied at concentrations greater than 1 μ M. These data showed that while the (K)RFK sequence alone is sufficient to activate latent TGF- β , other amino acid specificities appear to be required to properly orient the (K)RFK sequence within larger peptides and, similarly, within intact TSP.

The sequence GGWSHW inhibits sTSP-mediated activation of latent TGF- β

To determine whether the GGWSHW (SEQ ID NO:3) sequence competitively blocks the activation of TGF- β by the TSP trimer, latent TGF- β was incubated with sTSP in the presence of increasing concentrations of the peptide

GGWSHW (SEQ ID NO:3) and assayed for activation. In a soft agar NRK colony formation assay, TGF- β , combined with only sTSP up to concentrations of 1 nM, increased colony formation by approximately twofold over PBS baseline controls. However, when latent TGF- β was incubated with 1 nM sTSP in the presence of a 100-fold molar excess (1.1 μ M) of the GGWSHW (SEQ ID NO:3) peptide, TGF- β activity was completely inhibited. The inhibition of sTSP-mediated activation of latent TGF- β by the GGWSHW (SEQ ID NO:3) peptide was dependent on the peptide concentration, with 100% inhibition observed after applying the peptide at a concentration of 1.1 μ M.

10

Members of the TGF- β receptor superfamily also contain the sequence WSXW (SEQ ID NO:2) and it is possible that the decrease in activity observed may be due to competition of the peptide with active TGF- β for TGF- β receptor binding sites rather than a physical blocking of TSP-TGF- β interactions. To examine this possibility, human platelet TGF- β (R&D Systems, Minneapolis, Minnesota) was activated according to the manufacturer's instructions with 4mM HCl and pre-incubated with 1.1 μ M of the GGWSHW (SEQ ID NO:3) peptide for 30 minutes to maximize the possible interactions between the peptide and TGF- β . The TGF- β activity of this sample was assayed by soft agar NRK colony formation assay and compared with the TGF- β activity of activated human platelet TGF- β incubated without the peptide. The GGWSHW (SEQ ID NO:3) peptide had no effect on the activation of TGF- β as compared to human platelet TGF- β alone. Thus, the inhibitory effect of the GGWSHW (SEQ ID NO:3) peptide does not appear to be at the level of competitive blocking of TGF- β receptor binding sites.

25

The Sequence GGWSHW Blocks TGF- β -mediated Inhibition of Endothelial Cell Growth

BAE cells were seeded at 5×10^3 cells/well in a 24 well plate (Corning, Corning, New York) and allowed to attach overnight at 37°C, 5% CO₂. The wells were washed once with DMEM containing no FBS. Samples of the described peptides or intact sTSP were added in 0.5 ml 2.5% FBS/DMEM and incubated for four days at

30

37°C, 5% CO₂. Cells were fed after 48 hrs with additional sTSP or peptides and incubated an additional 48 hrs in a total volume of 1 ml of medium. Cells were then trypsinized and counted on a Coulter Cell Counter model ZM (Coulter Electronics, Hialeah, Florida). Inhibiting peptides resulted in higher levels of cell proliferation compared to peptides having no activity.

In these experiments, GGWSHW (SEQ ID NO:3) in 1000–10,000-fold molar excess blocked 36–47% of TSP-mediated BAE growth inhibition (Table IV). These experiments suggest that the inhibitory GGWSHW (SEQ ID NO:3) peptide can be an effective reagent to block TSP activation of latent TGF- β in a cellular environment. Other inhibiting peptides are expected to have the same effect on cell proliferation because of their similar action on TGF- β .

The Sequence KRFKQDGGWSHWSPWSSC (SEQ ID NO:45) Inhibits Proliferation of Endothelial Cells

Corneal bovine endothelial cells (BCE cells) were used at passages 2 through 8 (76). BCE cell cultures were maintained in DMEM (low glucose), containing 10% FCS, 4mM glutamine, 2.5 μ g/ml amphotericin B, and 500 U/ml each of penicillin G potassium and streptomycin sulfate (all media components were from Biofluids Inc., Rockville, Maryland). BCE cells were grown at 34°C in 5% CO₂. The medium was changed every 2–3 days.

Endothelial cell proliferation was measured using the CELL TITER 96TM assay (Promega, Madison, Wisconsin). 5 x 10³ cells were plated into each well of a 96-well culture plate in 0.5 or 5% FCS-containing medium together with the indicated concentrations of growth effectors. After 72 hrs, 15 μ l of dye solution were added to each well, and the plates were incubated for an additional four hrs. Solubilization solution was added and absorbance at 570 nm was determined after 24 hrs, as described by the manufacturer.

The activating peptide KRFKQDGGWSHWSPWSSC (SEQ ID NO:45) conjugated to FICOLL was a potent inhibitor of endothelial cell proliferation, with an inhibitory concentration $_{50}$ (IC_{50}) consistently less than $1\mu M$. The FICOLL carrier without peptide was inactive. The FICOLL conjugate of the activating peptide

5 GGWSHWSPWSSC (SEQ ID NO:46), which lacks the amino terminal basic amino acid sequence, was also strongly active for inhibiting proliferation of endothelial cells. Similar inhibitory activities were observed using cells grown in 0.5% or 5% fetal calf serum. Other peptides that activate TGF- β should have the same effect because of their action on TGF- β .

10

Enhancement of Wound Healing by Administration of the KRFK Peptide

A 2 cm by 1 cm wire mesh wound chamber is implanted into the backs of rats. After a wound healing response is initiated (day 4), the rats are given daily injections of 100–1000nM KRFK (SEQ ID NO:5), 1000 ng TGF- β , 1000 ng albumin

15 or vehicle control per injection site at the wound site. On day 9, the animals are sacrificed and tissues in the wound chamber are examined histologically and assayed for total protein and collagen content (by measurement of hydroxy-proline content). Relative levels of TGF- β are examined in the wound tissue by immunohistochemical techniques..

20

Alternatively, a six cm linear incision is made in the dorsal skin of a rat, the wound is coapted with surgical clamps and 100–1000nM KRFK, 1000 ng TGF- β , 1000 ng albumin (in 3% methylcellulose as a vehicle) or vehicle control per injection site is injected at the wound site. Other controls could include inactive analogs of

25 KRFK (SEQ ID NO:5), such as KRAK (SEQ ID NO:35), TRIR (SEQ ID NO:30) or KRWK (SEQ ID NO:37). After 7–10 days, wound strips are harvested and evaluated for tensile strength using a tensiometer and for histological analysis as described above. Enhanced wound healing would be determined by histological evaluation of cellularity of the wound site (measurement of DNA content), the presence of collagen fibrils, and

30 of re-epithelialization of the wound surface. Clinicians familiar with this condition would be able to make a determination that a statistically significant increase in the rate

of wound healing has occurred. For example, one skilled in the art could evaluate how much change in the DNA content is indicative of enhanced wound healing in a treated wound relative to an untreated wound. Also, a skilled artisan could readily determine the amount of re-epithelialization required for enhanced wound healing. Furthermore, one skilled in the art could readily assess the tensile strength of a wound in evaluating enhanced wound healing.

Prevention of Fibrosis by Administration of the GGWSHW Peptide

A 2 cm by 1 cm wire mesh wound chamber is implanted into the backs of rats. After a wound healing response is initiated (day 4), the rats are given daily injections of 100–1000nM GGWSHW (SEQ ID NO:3) peptides, 100–2000 ng TGF- β , 100–2000 ng albumin or vehicle control per injection site at the wound site. On day 9, the animals are sacrificed and tissues in the wound chamber are examined histologically and assayed for total protein and collagen content (by measurement of hydroxy-proline content). Relative levels of TGF- β are examined in the wound tissue by immunohistochemical techniques.

Alternatively, a six cm linear incision is made in the dorsal skin of a rat, the wound is coapted with surgical clamps and 100–1000nM GGWSHW (SEQ ID NO:3), 100–2000 ng TGF- β , 100–2000 ng albumin (in 3% methylcellulose as a vehicle) or vehicle control per injection site is injected into the wound site. Other controls could include inactive analogs of GGWSHW (SEQ ID NO:3), such as SHWWSS (SEQ ID NO:40), GGWSHY (SEQ ID NO:41) and GGWSKW (SEQ ID NO:42). After 7–10 days, the wound strips are harvested and evaluated for tensile strength using a tensiometer and for histological analysis as described above. The primary measure of fibrosis would be an evaluation of the collagen content of the wound by histological analysis with a trichrome stain for connective tissue and by measurement of hydroxyproline content of a defined wound area from a punch biopsy. Clinicians familiar with this condition would be able to make a determination that a statistically significant reduction in fibrosis has occurred. For example, one skilled in the art could evaluate how much change in the collagen content of a treated wound is

indicative of reduced fibrosis relative to an untreated wound. Also, a skilled artisan could readily determine the amount of hydroxyproline which is indicative of reduced fibrosis.

5 Topical Treatment of a Wound with TSP or Peptides from TSP to Enhance Wound Healing

In a clinical application, 1 µg to 100 mg of purified TSP or activating peptides from TSP are impregnated in a bandage which is applied directly to a wound or are incorporated into an ointment which is applied directly to the wound. A skilled
10 clinician would be able to determine the amount of TSP or peptides from TSP and length of treatment necessary to enhance wound healing, depending on the patient's age, size and the site and condition of the wound.

15 Topical Treatment of a Site of Potential Fibrosis with TSP Peptides to Reduce Fibrosis

In a clinical application, 1 µg to 100 mg of purified inhibiting peptides of TSP are impregnated in a bandage which is applied directly to a site of potential fibrosis or are incorporated into an ointment which is applied directly to a site of potential fibrosis. A skilled clinician would be able to determine the amount of
20 peptides and length of treatment with the peptides necessary to reduce fibrosis, depending on the patient's age, size and the condition of the site of potential fibrosis.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference
25 into this application in order to more fully describe the state of the art to which this invention pertains.

Although the present process has been described with reference to specific details of certain embodiments thereof, it is not intended that such details
30 should be regarded as limitations upon the scope of the invention except as and to the extent that they are included in the accompanying claims.

TABLE I. The minimal sequence required for activation of latent TGF- β is the RFK peptide sequence of TSP.

Sequence		Fold Activation of Latent TGF- β over Baseline
5	sTSP	$2x \pm 0$
	VTCGGGVQKRSRL (SEQ ID NO:29)	none
	KRFGQDGGWSHWSPWSS (SEQ ID NO:15)	$2x \pm 0$
	KRFGQDGGWSHWSP (SEQ ID NO:14)	$2.3x \pm 0.2$
10	KRFGQDGGWSHW (SEQ ID NO:16)	$1.9x \pm 0.2$
	KRFGQDGGWWSP (SEQ ID NO:17)	$2.1x \pm 0.2$
	KRFGQDGG (SEQ ID NO:9)	$2.1x \pm 0.1$
	KRFG (SEQ ID NO:5)	$2x \pm 0.1$
	RFK (SEQ ID NO:18)	$2.5x \pm 0.5$
15		

TABLE II. Certain amino acids within the KRFK sequence of TSP are necessary for TGF- β stimulating activity.

Sequence	Fold Activation of Latent TGF- β over Baseline
sTSP	$2x \pm 0$
KRFB (SEQ ID NO:5)	$2x \pm 0.1$
TRIR (SEQ ID NO:30)	none
QRFB (SEQ ID NO:8)	$2X \pm 0$
HRFB (SEQ ID NO:6)	$2X \pm 0$
KKFB (SEQ ID NO:32)	2.2 ± 0.15
KQFB (SEQ ID NO:33)	none
KRFQ (SEQ ID NO:34)	none
KRAK (SEQ ID NO:35)	none
KRYK (SEQ ID NO:36)	none
KRWK (SEQ ID NO:37)	none
RFB (SEQ ID NO:18)	$2.5x \pm 0.5$
RFR (SEQ ID NO:43)	none
RWR (SEQ ID NO:44)	none

TABLE III: Peptides which Activate or Inhibit Activation of Latent TGF- β

Activating Peptides	Inhibiting Peptides
KRFK (SEQ ID NO:5)	WNDWI (SEQ ID NO:19)
HRFK (SEQ ID NO:6)	GGWSHW (SEQ ID NO:3)
RKPK (SEQ ID NO:7)	LSKL (SEQ ID NO:21)
QRFK (SEQ ID NO:8)	DGWSPW (SEQ ID NO:23)
RFK (SEQ ID NO:18)	GGWGPW (SEQ ID NO:24)
KRFKQDGG (SEQ ID NO:9)	WSPWS (SEQ ID NO:25)
RWRPWTAWSE (SEQ ID NO:10)	GWSHW (SEQ ID NO:26)
TAYRWRLSHRPKTGIRV (SEQ ID NO:11)	WSHWS (SEQ ID NO:27)
KRFKQDGGASHASPASS (SEQ ID NO:12)	WSSWS (SEQ ID NO:20)
KRFKQDGGASHASP (SEQ ID NO:13)	retro-inverso acetyl WHSWAA (SEQ ID NO:28)-NH ₂
KRFKQDGGWSHWSPWSSC (SEQ ID NO:45)	AAWSHW (SEQ ID NO:22)
GGWSHW2SPWSSC (SEQ ID NO:46)	

TABLE IV. The inhibitory peptide, GGWSHW, blocks TGF- β -mediated inhibition of BAE cell growth.

Treatment of BAE Cells	Cells/Well on Day 4
2.5% FBS	165,491 \pm 1530
TSP 1.0 μ g/ml	64,331 \pm 3841
TSP + GGWSHW (SEQ ID NO: 3) (1.1 μ M)	100,522 \pm 2990
TSP + GGWSHW (SEQ ID NO:3) (11 μ M)	112,276 \pm 3730

REFERENCES

1. Allen-Hoffman, B.L., C.L. Crankshaw, and D.F. Mosher. 1988. Transforming Growth Factor β Increases Cell Surface Binding and Assembly of Exogenous (Plasma) Fibronectin by Normal Human Fibroblasts. *Mol. Cell Biol.* 8:4234-4242.
2. Bagavandoss, P., and J.W. Wilks. 1990. Specific Inhibition of Endothelial Cell Proliferation by Thrombospondin. *Biochem. Biophys. Res. Commun* 170:867-872.
3. Barnard, J.A., R.M. Lyons, and H.L. Moses. 1990. The Cell Biology of TGF- β . *Biochem. Biophys. Res. Commun.* 163: 56-63.
4. Bodmer, S., K. Strommer, K. Frei, C. Siepl, N. de Tribolet, I. Heid, and A. Fontana. 1989. Immunosuppression and Transforming Growth Factor- β in Glioblastoma. Preferential Production of Transforming Growth Factor- β_2 . *J. Immunol.* 143:3222-3229.
5. Bornstein, P. 1992. Thrombospondins - Structure and Regulation of Expression. *FASEB Journal.* 6:3290-3299.
6. Brown, P.D., L.M. Wakefield, A.D. Levinson, and M.B. Sporn. 1990. Physicochemical Activation of Recombinant Latent Transforming Growth Factor-betas 1,2, and 3. *Growth Factors* 3:35-43.
7. Browne, P.C., J.J. Miller, and T.C. Detwiler. 1988. Kinetics of the Formation of Thrombin-Thrombospondin Complexes: Involvement of a 77-kDa Intermediate. *Arch. Biochem. and Biophys.* 151:534-538.
8. Brunner, A.M., L.E. Gentry, J.A. Cooper, A.F. Purchio. 1988. Recombinant Type I Transforming Growth Factor β Precursor Produced in Chinese Hamster Ovary Cells is Glycosylated and Phosphorylated. *Mol. Cell Biol.* 8:2229-2232.
9. Brunner, A.M., H. Marquardt, A.R. Malacko, M.N. Lioubin, and A.F. Purchio. 1989. Site-Directed Mutagenesis of Cysteine Residues in the Pro Region of the Transforming Growth Factor β 1 Precursor. *J. Biol. Chem.* 264:13660-13664.
10. Cheifetz, S. and J. Massague. 1989. Transforming Growth Factor- β (TGF- β) Receptor Proteoglycan. *J. Biol. Chem.* 264:12025-12028.
11. Dardik, R. and J. Lahav. 1991. Cell-binding domain of endothelial cell thrombospondin: localization to the 70-kDa core fragment and determination of binding characteristics. *Biochemistry* 30:9378-9386.

12. Dennis, P.A., D.B. Rifkin. 1991. Cellular Activation of Latent Transforming Growth Factor- β Requires Binding to the Cation-Independent Mannose-6-Phosphate/Insulin-like Growth Factor Type II Receptor. *Proc. Nat. Acad. Sci. USA*.
13. Flaumenhaft, R., M. Ave, P. Mignatti, and D.B. Rifkin. 1992. bFGF Induced Activation of Latent TGF- β in Endothelial Cells: Regulation of Plasminogen Activator Activity. *J. Cell Biol.* 118:901-909.
14. Frazier, W.A. 1987. Thrombospondin: a Modular Adhesive Glycoprotein of Platelets and Nucleated Cells. *J. Cell. Biol.* 105:625-632.
15. Gentry, L.E., M.N. Lioubin, A.F. Purchio, and H. Marquardt. 1988. Molecular Events in the Processing of Recombinant Type I Pre-Pro-Transforming Growth Factor beta to the Mature Polypeptide. *Mol. Cell Biol.* 8:4162-4168.
16. Gentry, L.E., N.R. Webb, J. Lim, A.M. Brunner, J.E. Ranchalis, D.R. Twardzik, M.N. Lioubin, H. Marquardt, A.F. Purchio. 1987. Type I Transforming Growth Factor Beta: Amplified Expression and Secretion of Mature and Precursor Polypeptides in Chinese Hamster Ovary Cells. *Mol. Cell Biol.* 7:3418-3427.
17. Gentry, L.E. and B.W. Nash. 1990. The Pro Domain of Pre-Pro Transforming Growth Factor- β 1 when Independently Expressed is a Functional Binding Protein for the Mature Growth Factor. *Biochem.* 29:6851-6857.
18. Hannan, R.L., Kourembanas, K.C. Flanders, S. J. Rogelj, A. B. Roberts, D. V. Faller, and M. Klagsbrun. 1988. Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. *Growth Factors* 1:7-17.
19. Huber, D., A. Fontant, and S. Bodmer. 1991. Activation of Human Platelet Derived Latent Transforming Growth Factor- β 1 by Human Glioblastoma Cells. *Biochem. J.* 277:165-173.
20. Jullien, P., T.M. Berg, D.A. Laurence. 1989. Acidic Cellular Environments: Activation of Latent TGF- β and Sensitization of Cellular Responses to TGF- β and EGF. *Int. J. Cancer.* 43:886-891.
21. Kovacina, K.S., G. Steele-Perkins, A.F. Purchio, M. Lioubin, K. Miyazono, C-H. Heldin, and R.A. Roth. 1989. Interactions of Recombinant and Platelet Transforming Growth Factor- β 1 with the Insulin-like Growth Factor II/ Mannose 6-Phosphate Receptor. *Biochem. Biophys. Res. Commun.* 160:393-403.

22. Lyons, R.M., J. Keski-Oja, and H.L. Moses. 1988. Proteolytic Activation of Latent Transforming Growth Factor- β from Fibroblast Conditioned Medium. *J. Cell Biol.* 106:1659-1665.
23. Lyons, R.M., L.E. Gentry, A.F. Purchio, and H.L. Moses. 1990. Mechanism of Activation of Latent Recombinant Transforming Growth Factor β 1 by Plasmin. *J. Cell Biol.* 110:1361-1367.
24. Majack, R.A., S. Coates-Cook, and P. Bornstein. 1986. Control of Smooth Muscle Cell Growth by Components of the Extracellular Matrix: Autocrine Role for Thrombospondin. *Proc. Nat. Acad. Sci. USA* 83:9050-9054.
25. Massague J., T. Endo, B. Nadal-Ginard, and S. Cheifetz. 1986. Type β Transforming Growth Factor is an Inhibitor of Myogenic Differentiation. *Proc. Nat. Acad. Sci. USA* 83:8206-8210.
26. Massague, J. et al. 1992. Transforming Growth Factor- β . *Cancer Surveys* 12: Tumour Suppressor Genes, the Cell Cycle and Cancer.
27. Miyazono, K., U. Hellman, C. Wernstedt, and C.H. Heldin. 1988. Latent High Molecular Weight Complex of Transforming Growth Factor β 1; Purification from Human Platelets and Structural Characterization. *J. Biol. Chem.* 263:6407-6415.
28. Miyazono, K. C.H. Heldin. 1989. Role for Carbohydrate Structures in TGF- β Latency. *Nature (London)* 338:158-160.
29. Mooradian, D.L., R.C. Lucas, J.A. Weatherbee, and L.T. Furcht. 1989. Transforming Growth Factor-beta 1 Binds to Immobilized Fibronectin. *J. Cell. Biochem.* 41:189-200.
30. Mosher, D.F. 1990. Physiology of Thrombospondin. *Annu. Rev. Med.* 41:85-97.
31. Mueller, G., J. Behrens, U. Nussbaumer, P. Bohlen, and W. Birchmeier. 1987. Inhibitory Action of TGF- β on Endothelial Cells. *Proc. Nat. Acad. Sci., USA* 84:5600-5604.
32. Murphy-Ullrich, J.E., L. G. Westrick, J.D. Esko, and D.F. Mosher. 1988. Altered metabolism of thrombospondin by Chines Hamster Ovary cells defective in glycosaminoglycan synthesis. *J. Biol. Chem.* 263:6400-6406.
33. Murphy-Ullrich, J.E., and M. Hk. 1989. Thrombospondin Modulates Focal Adhesions in Endothelial Cells. *J. Cell Biol.* 109:1309-1319.

34. Murphy-Ullrich, J.E., S. Schultz-Cherry, and M. Höök. 1992. Transforming Growth Factor- β Complexes With Thrombospondin. *Mol. Biol. of the Cell* 3:181-188.
35. Paralkar, V.M., S. Vukicevic, and A.H. Reddi. 1991. Transforming Growth Factor Beta Type I Binds to Collagen IV of Basement Membrane Matrix: Implications for Development. *Developmental Biol.* 143:303-308.
36. Phan, S.H., R.G. Dillon, B.M. McGarry, and V.M. Dixit. 1989. Stimulation of Fibroblast Proliferation by Thrombospondin. *Biochem. Biophys. Res. Commun.* 163:56-63.
37. Pircher, R., P. Jullien and D.A. Lawrence. 1986. β -Transforming Growth Factor is Stored in Human Blood Platelets as a Latent High Molecular Weight Complex. *Biochem. Biophys. Res. Comm.* 136:30-37.
38. Purchio, A.F., J.A. Cooper, A.M. Brunner, M.N. Lioubin, L.E. Gentry, K.S. Kovacina, R.A. Roth, H. Marquardt. 1988. Identification of Mannose-6-Phosphate in two Asparagine-Linked Sugar Chains of Recombinant Transforming Growth Factor β -1 Precursor. *J. Biol. Chem.* 264:14211-14215.
39. Roberts, A.B., M.B. Sporn, R.K. Assoian, J. M. Smith, N.S. Roche, L. M. Wakefield, U.I. Heine, L. A. Liotta, V. Falanga, J. H. Kehrl, A S. Fauci. 1986. Transforming growth Factor Type-beta: Rapid Induction of Fibrosis and Angiogenesis *in vivo* and Stimulation of Collagen Formation *in vitro*. *Proc. Nat. Acad. Sci.* 83:4167-4171.
40. Sato, Y., D.B. Rifkin. 1989. Inhibition of Endothelial Cell Movement by Pericytes and Smooth Muscle Cells: Activation of a Latent TGF- β 1-like Molecule by Plasmin During Co-Culture. *J. Cell Biol.* 109:309-315.
41. Sato, Y., R. Tsuboi, R. Lyons, H. Moses, and D.B. Rifkin. 1990. Characterization of the Activation of Latent TGF- β by Co-Cultures of Endothelial Cells and Pericytes of Smooth Muscle Cells: A Self-Regulating System. *J. Cell Biol.* 111:757-764.
42. Taraboletti, G., D. Roberts, L.A. Liotta, and R. Giavazzia. 1990. Platelet Thrombospondin Modulates Endothelial Cell Adhesion, Motility, and Growth: A Potential Angiogenesis Regulatory Factor. *J. Cell Biol.* 111:765-772.
43. Wakefield, L.M., T.S. Winokur, R.S. Hollands, K. Christopherson, A.D. Levison, and M.B. Sporn. 1990. Recombinant Latent Transforming Growth Factor Beta 1 has a Longer Plasma Half-Life in rats than Active Transforming Growth Factor beta 1, and a Different Tissue Distribution. *J. Clin. Invest.* 86:1976-1984.

44. Yamaguchi, Y., D.M. Mann, and E. Ruoslahti. 1990. Negative Regulation of Transforming Growth Factor-beta by the Proteoglycan Decorin. *Nature* 346:281-284.
45. Zentalla, A. and J. Massague. 1992. TGF- β Induces Myoblast Differentiation in the Presence of Mitogens. *Proc. Nat. Acad. Sci.* 89:5176-5180.
46. Raghow, *Chest* (Supplement, 33rd Annual Thomas L. Petty Aspen Lung Conference) 99:61S-65S (1991).
47. Tuszyński, G.P. *et al.* 1992. "Biological Activities of Peptides and Peptide Analogues Derived from Common Sequences Present in Thrombospondin, Properdin and Malarial Proteins. *J. Cell Biol.* 116:209-217.
48. Frazier, 1991.
49. Lahav, J. 1993. "The Functions of Thrombospondin and its Involvement in Physiology and Pathophysiology." *Biochimica et Biophysica Acta* 1182:1-14 (1993)
50. Penttinen *et al.* 1988. *PNAS*, 85:1105-1108.
51. Vogel *et al.* 1993. "Modulation of Endothelial Cell Proliferation, Adhesion, and Motility by Recombinant Heparin-Binding Domain and Synthetic Peptides from the Type I Repeats of Thrombospondin." *J. Cellular Biochem.* 53:1-11.
52. Majack *et al.* 1988.
53. Prater *et al.* 1992.
54. Asch *et al.* 1992.
55. Tolsma *et al.* 1993.
56. Guo, N. *et al.* 1992. "Heparin-Binding Peptides from the Type I Repeats of Thrombospondin." *J. Biol. Chem.*, 267:19349-19355.
57. Sipes *et al.* 1993. "Inhibition of Fibronectin Binding and Fibronectin-Mediated Cell Adhesion to Collagen by a Peptide from the Second Type I Repeat of Thrombospondin." *J. Cell Biol.*, 121:469-477 (1993).
58. Wharton *et al.* 1991.
59. Bazan 1990.
60. Sandritter *et al.* 1979. Color Atlas and Textbook of Histopathology, Year Book Medical Publishers, Inc., Chicago, Illinois.

61. Harlow and Lane. 1988. Antibodies, A Laboratory Manual, Cold Springs Harbor Laboratory, Cold Spring Harbor, New York, New York.
62. Sporn *et al.* 1983. "Polypeptide Transforming Growth Factors Isolated from Bovine Sources and Used for Wound Healing *In Vivo*." *Science*, 219:1329-1330.
63. Cromack *et al.* 1993. "Acceleration of Tissue Repair by Transforming Growth Factor β 1: Identification of *In Vivo* Mechanism of Action with Radiotherapy-Induced Specific Healing Deficits." *Surgery*, 113:36-42.
64. Cotron *et al.* 1989. Robbins Pathologic Basis of Disease, 4th Edition, W.B. Saunder Co., Philadelphia, PA.
65. Lehninger *et al.* 1993. Principles of Biochemistry, 2d Ed., Worth Publishers, New York, New York.
66. Amento *et al.* 1991. "TGF- β and Wound Healing," In: Clinical Applications of TGF- β , Ciba Foundation Symposium, 57:115-123, John Wiley and Sons.
67. Ksander, G.A. *et al.* 1990. "Transforming Growth Factors- β 1 and β 2 Enhance Connective Tissue Formation in Animal Models of Dermal Wound Healing by Secondary Intent," *Annals of NY Acad. Sci.*, 593:135-147.
68. Davidson, J.M. *et al.* 1990. "Manipulation of the Wound Healing Process with Basic FGF," *Annals NY Acad. Sci.*, 638:306-315.
69. Mazue, G. *et al.* 1990. "Preclinical and Clinical Studies with Recombinant Human Fibroblast Growth Factor," *Annals NY Acad. Sci.*, 638:329-340.
70. Lawler & Hynes. 1986. *J. Cell Biol.*, 103:1635-1648.
71. Guo *et al.* 1992. "Heparin- and Sulfatide-Binding Peptides from the Type I Repeats of Human Thrombospondin Promote Melanoma Cell Adhesion." *P.N.A.S.*, 89:2040-2044.
72. Cardin & Weintraub. 1989. *Arteriosclerosis*, 9:21-32.
73. Murphy-Ullrich *et al.* 1993. *J. Biol. Chem.*, 268:26784-26789.
74. Choreo & Goodman. 1993. *Acc. Chem. Res.* 26:266-273.
75. Olson *et al.* 1993. *J. Med. Chem.* 36:3039-3049.
76. Munjal *et al.* 1990.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: MURPHY-ULLRICH, JOANNE E.
ROBERTS, DAVID D.
SCHULTZ-CHERRY, STACEY
KRUTZSCH, HENRY C.
- (ii) TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
STIMULATING AND INHIBITING TGF-BETA ACTIVITY
- (iii) NUMBER OF SEQUENCES: 46
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: NEEDLE & ROSENBERG, P.C.
 - (B) STREET: 127 Peachtree Street, NE
 - (C) CITY: Atlanta
 - (D) STATE: Georgia
 - (E) COUNTRY: USA
 - (F) ZIP: 30303-1811
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: SPRATT, GWENDOLYN D.
 - (B) REGISTRATION NUMBER: 36,016
 - (C) REFERENCE/DOCKET NUMBER: 2180.0181
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (404) 688-0770
 - (B) TELEFAX: (404) 688-9880

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys Ser Val Thr Cys Gly
1 5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Trp Ser Xaa Trp
1

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Gly Gly Trp Ser His Trp
1 5

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Trp Ser His Trp
1

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Lys Arg Phe Lys
1

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

47

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

His Arg Phe Lys

1

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Arg Lys Pro Lys

1

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gln Arg Phe Lys

1

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

48

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys Arg Phe Lys Gln Asp Gly Gly
1 5

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Arg Trp Arg Pro Trp Thr Ala Trp Ser Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Thr Ala Tyr Arg Trp Arg Leu Ser His Arg Pro Lys Thr Gly Ile
Arg
1 5 10
15
Val

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys Arg Phe Lys Gln Asp Gly Gly Ala Ser His Ala Ser Pro Ala
Ser
1 5 10 15

Ser

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Lys Arg Phe Lys Gln Asp Gly Gly Ala Ser His Ala Ser Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

50

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys	Arg	Phe	Lys	Gln	Asp	Gly	Gly	Trp	Ser	His	Trp	Ser	Pro
1				5					10				

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Lys	Arg	Phe	Lys	Gln	Asp	Gly	Gly	Trp	Ser	His	Trp	Ser	Pro	Trp
Ser														
1				5				10					15	

Ser

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Lys	Arg	Phe	Lys	Gln	Asp	Gly	Gly	Trp	Ser	His	Trp
1				5				10			

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Lys	Arg	Phe	Lys	Gln	Asp	Gly	Gly	Trp	Trp	Ser	Pro
1				5					10		

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Arg	Phe	Lys
1		

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Trp Asn Asp Trp Ile
1 5

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Trp Ser Ser Trp Ser
1 5

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Leu Ser Lys Leu
1

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

53

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ala Ala Trp Ser His Trp
1 5

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Asp Gly Trp Ser Pro Trp
1 5

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Gly Gly Trp Gly Pro Trp
1 5

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Trp Ser Pro Trp Ser
1 5

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Gly Trp Ser His Trp
1 5

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Trp Ser His Trp Ser
1 5

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Trp His Ser Trp Ala Ala
1 5

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Val Thr Cys Gly Gly Gly Val Gln Lys Arg Ser Arg Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Thr Arg Ile Arg
1

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

- Ala Arg Phe Lys

- 1

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

- Lys Lys Phe Lys

- 1

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Lys Gln Phe Lys
1

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Lys Arg Phe Gln
1

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Lys Arg Ala Lys
1

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Lys Arg Tyr Lys
1

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Lys Arg Trp Lys
1

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Ala Ser Leu Arg Gln Met Lys Lys Thr Arg Gly Thr Leu Leu Ala
Leu
1 5 10 15

Glu Arg Lys Asp His Ser
20

59

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu Val
Lys
1 5 10 15

Gly Pro Asp

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Ser His Trp Trp Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

60

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Gly Gly Trp Ser His Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Gly Gly Trp Ser Lys Trp
1 5

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Arg Phe Arg
1

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

61

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Arg Trp Arg
1

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Lys Arg Phe Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp
Ser
1 5 10 15

Ser Cys

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys
1 5 10

What is claimed is:

1. A method of stimulating transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of thrombospondin effective to convert latent transforming growth factor-beta to active transforming growth factor-beta.
2. A method of stimulating transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of a purified activating peptide of thrombospondin effective to convert latent transforming growth factor-beta to active transforming growth factor-beta.
3. A method of stimulating transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of a purified activating peptide having 3 to 30 amino acids, wherein the peptide comprises a subsequence $R_1-X_1-X_2-X_3-R_2$, wherein X_1 is selected from the group consisting of Arg and Lys, X_2 is selected from the group consisting of Pro and Phe, X_3 is selected from the group consisting of Lys and Arg, R_1 is H, acyl, or a peptide of from 1 to 26 amino acids, R_2 is H, NH_2 , or a peptide of from 1 to 26 amino acids and wherein the peptide converts latent transforming growth factor-beta to active transforming growth factor-beta.
4. A method of stimulating transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of a purified activating peptide selected from the group consisting of KRFK (SEQ ID NO:5), HRFK (SEQ ID NO:6), RKPK (SEQ ID NO:7), QRFK (SEQ ID NO:8), KRFKQDGG (SEQ ID NO:9), RWRPWTAWSE (SEQ ID NO:10), TAYRWRLSHRPKTGIRV (SEQ ID NO:11), KRFKQDGGASHASP (SEQ ID NO:12), KRFKQDGGASHASP (SEQ ID NO:13), KRFKQDGGWSHWSP (SEQ ID NO:14), KRFKQDGGWSHWSPWSS (SEQ ID NO:15), KRFKQDGGWSHW (SEQ ID NO:16) and KRFKQDGGWWSP (SEQ ID NO:17).

5. The method of Claim 2, wherein the purified activating peptide consists of the amino acid sequence RFK (SEQ ID NO:18).
6. A method of inhibiting the stimulation of transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of a ligand specific for thrombospondin effective to bind thrombospondin and prevent conversion of latent transforming growth factor-beta to active transforming growth factor-beta.
7. A method of inhibiting the stimulation of transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of a purified inhibiting peptide having a sequence that corresponds to a sequence of four consecutive amino acids of thrombospondin, effective to inhibit the conversion of latent transforming growth factor-beta to active transforming growth factor-beta.
8. A method of inhibiting the stimulation of transforming growth factor-beta activity, comprising contacting latent transforming growth factor-beta with an amount of a purified inhibiting peptide selected from the group consisting of GGWSHW (SEQ ID NO:3), WNDWI (SEQ ID NO:19), WSSWS (SEQ ID NO:20), LSKL (SEQ ID NO:21), AAWSHW (SEQ ID NO:22), DGWSPW (SEQ ID NO:23), GGWGPW (SEQ ID NO:24), WSPWS (SEQ ID NO:25), GWSHW (SEQ ID NO:26) and WSHWS (SEQ ID NO:27).
9. A method of enhancing wound healing, comprising administering to a wound site an amount of thrombospondin effective to convert latent transforming growth factor-beta to active transforming growth factor-beta, the activation of transforming growth factor-beta resulting in enhanced wound healing.

10. A method of enhancing wound healing, comprising administering to a wound site an amount of a purified activating peptide from TSP effective to convert latent transforming growth factor-beta to active transforming growth factor-beta, the activation of transforming growth factor-beta resulting in enhanced wound healing.

11. The method of Claim 10, wherein the purified activating peptide consists of the amino acid sequence KRFK (SEQ ID NO:5), HRFK (SEQ ID NO:6), RKPK (SEQ ID NO:7), QRFK (SEQ ID NO:8), KRFKQDGG (SEQ ID NO:9), RWRPWTAWSE (SEQ ID NO:10), TAYRWRLSHRPKTGIRV (SEQ ID NO:11), KRFKQDGGASHASP (SEQ ID NO:12), KRFKQDGGASHASP (SEQ ID NO:13), KRFKQDGGWSHWSP (SEQ ID NO:14), KRFKQDGGWSHWSPWSS (SEQ ID NO:15), KRFKQDGGWSHW (SEQ ID NO:16) and KRFKQDGGWWSP (SEQ ID NO:17).

12. The method of Claim 10, wherein the purified activating peptide consists essentially of the amino acid sequence RFK (SEQ ID NO:18).

13. A method of preventing fibrosis stimulated by transforming growth factor-beta in pathology, comprising administering to a site of potential fibrosis an amount of a ligand specific for thrombospondin effective to bind thrombospondin, thereby preventing activation of TGF- β , resulting in reduced fibrosis.

14. A method of preventing fibrosis stimulated by transforming growth factor-beta in pathology, comprising administering to a site of potential fibrosis an amount of a purified inhibiting peptide from TSP effective to inhibit the conversion of latent transforming growth factor-beta to active transforming growth factor-beta, resulting in reduced fibrosis.

15. The method of Claim 14, wherein the purified inhibiting peptide is selected from the group consisting of WNDWI (SEQ ID NO:19), WSSWS (SEQ ID NO:20), LSKL (SEQ ID NO:21), AAWSHW (SEQ ID NO:22), DGWSPW (SEQ ID NO:23), GGWGPW (SEQ ID NO:24), WSPWS (SEQ ID NO:25), GWSHW (SEQ ID NO:26) and WSHWS (SEQ ID NO:27).

16. The method of Claim 14, wherein the purified inhibiting peptide consists essentially of the amino acid sequence GGWSHW (SEQ ID NO:3).

17. A method of blocking transforming growth factor-beta-mediated inhibition of endothelial cell proliferation, comprising contacting endothelial cells with an amount of a ligand specific for thrombospondin effective to bind thrombospondin, thereby preventing activation of thrombospondin, resulting in proliferation of endothelial cells.

18. A method of blocking transforming growth factor-beta-mediated inhibition of endothelial cell proliferation, comprising contacting endothelial cells with an amount of a purified inhibiting peptide from TSP effective to inhibit conversion of latent transforming growth factor-beta to active transforming growth factor-beta, resulting in proliferation of endothelial cells.

19. The method of Claim 18, wherein the purified inhibiting peptide is selected from the group consisting of WNDWI (SEQ ID NO:19), WSSWS (SEQ ID NO:20), LSKL (SEQ ID NO:21), AAWSHW (SEQ ID NO:22), DGWSPW (SEQ ID NO:23), GGWGPW (SEQ ID NO:24), WSPWS (SEQ ID NO:25), GWSHW (SEQ ID NO:26) and WSHWS (SEQ ID NO:27).

20. The method of Claim 18, wherein the purified inhibiting peptide consists essentially of the amino acid sequence GGWSHW (SEQ ID NO:3).

21. A purified peptide having 3 to 30 amino acids, wherein the peptide comprises a subsequence $R_1-X_1-X_2-X_3-R_2$, wherein X_1 is selected from the group consisting of Arg and Lys, X_2 is selected from the group consisting of Pro and Phe, X_3 is selected from the group consisting of Lys and Arg, R_1 is H, acyl, or a peptide of from 1 to 26 amino acids, R_2 is H, NH_2 , or a peptide of from 1 to 26 amino acids and wherein the peptide converts latent transforming growth factor-beta to active transforming growth factor-beta.
22. The peptide according to Claim 21, wherein the peptide is selected from the group consisting of RFK (SEQ ID NO:18) KRFK (SEQ ID NO:5), HRFK (SEQ ID NO:6), RKPK (SEQ ID NO:7), QRFK (SEQ ID NO:8), KRFKQDGG (SEQ ID NO:9), TAYRWRLSHRPKTGIRV (SEQ ID NO:11), and KRFKQDGGASHPASS (SEQ ID NO:12).
23. The peptide consisting essentially of the amino acid sequence RWRPWTAWSE, defined in the Sequence Listing as SEQ ID NO:10.
24. The peptide according to Claim 21, wherein the peptide is conjugated to a water soluble polymer.
25. The peptide according to Claim 21, wherein the peptide is selected from the group consisting of partial and full retro-inverso peptide sequences.
26. A purified peptide selected from the group consisting of acetyl-WHSWAA-NH₂ (SEQ ID NO:28) and LSKL (SEQ ID NO:21).
27. The peptide according to Claim 26, wherein the peptide is selected from the group of partial and full retro-inverso peptide sequences.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09193

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A61K 38/00, 38/16, 39/00, 39/395; C07K 5/00, 14/00 US CL : 424/130.1, 139.1, 152.1; 514/2, 8; 530/350, 387.25 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/130.1, 139.1, 152.1; 514/2, 8; 530/350, 387.25 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, DIALOG, BIOSIS, EMBASE, CA, MEDLINE, WPI, INTELLEGENETICS search terms: thrombospondin, transforming growth factor and beta, TGF-beta, wound healing, fibrosis				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	Immunol. Today, Volume 10, No. 8, issued 1989, S.M. Wahl et al., "Inflammatory and Immunomodulatory Roles of TGF- β ", pages 258-261, see entire document.	1-27		
Y	Proc. Natl. Acad. Sci. USA, Volume 87, issued September 1990, D.J. Good et al., "A Tumor Suppressor-Dependent Inhibitor of Angiogenesis Is Immunologically and Functionally Indistinguishable from a Fragment of Thrombospondin", pages 6624-6628, see entire document.	1-27		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 07 OCTOBER 1994		Date of mailing of the international search report 25 NOV 1994		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer PHILLIP GAMBEL <i>W. Lyza for</i> Telephone No. (703) 308-0196		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/09193

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. Cell Biol., Volume 116, No. 1, issued January 1992, G. P. Tuszynski et al., "Biological Activities of Peptides and Peptide Analogues Derived from Common Sequences Present in Thrombospondin, Properdin, and Malarial Proteins", pages 209-217, see entire document.	1-27
Y	Biochemistry, Volume 30, issued 1991, R. Dardik et al., "Cell Binding Domain of Endothelial Cell Thrombospondin: Localization to the 7-kDa Core Fragment and Determination of Binding Characteristics", pages 9378-9386, see entire document.	1-27